Litcius/Paper detail

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial

Igor Smolenov, Htay Htay Han, Ping Li, Carmen Baccarini, Carole Verhoeven, Frank W. Rockhold, Sue Ann Costa Clemens, Donna M. Ambrosino, Peter Richmond, George R. Siber, Joshua G. Liang, Ralf Clemens

2022The Lancet Infectious Diseases23 citationsDOIOpen Access PDF

Topics & Concepts

ReactogenicityPlaceboMedicineVaccinationAdverse effectRandomized controlled trialCoronavirus disease 2019 (COVID-19)Vaccine efficacyInternal medicineClinical trialInfluenza vaccineImmunologyVirologyAntibodyImmunogenicityPathologyInfectious disease (medical specialty)DiseaseAlternative medicineSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial | Litcius